Schizophrenia and Disorders with Psychotic Features  >>  ulotaront (SEP-363856)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ulotaront (SEP-363856) / Otsuka
NCT01940159: A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

Completed
1
48
US
SEP-363856, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
03/14
03/14
NCT01994473: Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

Completed
1
48
US
SEP-363856, Placebo, SEP-363856 Open Label
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
12/14
12/14
NCT01972711: Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics

Completed
1
105
Europe
SEP-363856, Amisulpride, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
07/15
07/15

Download Options